T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

(2021) Nengzhi Pang et al.   Journal of Hematology & Oncology

Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens

(2020) Geoffrey M. Lynn et al.   NATURE BIOTECHNOLOGY

Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)

(2020) Philip George et al.   BMJ Open

Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy

(2020) Ji-Yoon Noh et al.   Journal of Immunology Research

mTORC1 Signaling Controls TLR2-Mediated T-Cell Activation by Inducing TIRAP Expression

(2020) Takayuki Imanishi et al.   Cell Reports

CAR-NK cells: A promising cellular immunotherapy for cancer

(2020) Guozhu Xie et al.   EBioMedicine

Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies

(2019) Matthew R. Collinson-Pautz et al.   LEUKEMIA

Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines

(2019) Benjamin L. Lu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Toll-Like Receptor 7 Activation Enhances CD8+ T Cell Effector Functions by Promoting Cellular Glycolysis

(2019) Qian Li et al.   Frontiers in Immunology

The Role of TLRs in Anti-cancer Immunity and Tumor Rejection

(2019) Zuzanna Urban-Wojciuk et al.   Frontiers in Immunology

MYD88L265P Mutation in Lymphoid Malignancies

(2018) Xinfang Yu et al.   CANCER RESEARCH

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia

(2018) Jianyu Weng et al.   Journal of Hematology & Oncology

Clinical use of lentiviral vectors

(2018) Michael C. Milone et al.   LEUKEMIA

Mechanisms of BCG immunotherapy and its outlook for bladder cancer

(2018) Caroline Pettenati et al.   Nature Reviews Urology

Toll-Like Receptors, Associated Biological Roles, and Signaling Networks in Non-Mammals

(2018) Li Nie et al.   Frontiers in Immunology

TLR Stimulation During T-cell Activation Lowers PD-1 Expression on CD8+ T Cells

(2018) Christopher D. Zahm et al.   Cancer Immunology Research

Costimulation through TLR2 Drives Polyfunctional CD8+ T Cell Responses

(2018) Fiamma Salerno et al.   JOURNAL OF IMMUNOLOGY

Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells

(2017) Y Lai et al.   LEUKEMIA

Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models

(2017) Melinda Mata et al.   Cancer Discovery

Limb proportions show developmental plasticity in response to embryo movement

(2017) A. S. Pollard et al.   Scientific Reports

B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice

(2016) G. Knittel et al.   BLOOD

Direct TLR-2 Costimulation Unmasks the Proinflammatory Potential of Neonatal CD4+T Cells

(2016) Brian D. Sinnott et al.   JOURNAL OF IMMUNOLOGY

Toll-Like Receptor 11 (TLR11) Interacts with Flagellin and Profilin through Disparate Mechanisms

(2016) Hirotsugu Hatai et al.   PLoS One

Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice

(2014) Yufei Zhang et al.   CLINICAL IMMUNOLOGY

The Myeloid Differentiation Factor 88 (MyD88) Is Required for CD4+ T Cell Effector Function in a Murine Model of Inflammatory Bowel Disease

(2014) M. Fukata et al.   JOURNAL OF IMMUNOLOGY

Activated Human Neonatal CD8+ T Cells Are Subject to Immunomodulation by Direct TLR2 or TLR5 Stimulation

(2014) M. McCarron et al.   JOURNAL OF IMMUNOLOGY

Triggering Through Toll-like Receptor 2 Limits Chronically Stimulated T-helper Type 1 Cells From Undergoing Exhaustion

(2014) Sathi Babu Chodisetti et al.   JOURNAL OF INFECTIOUS DISEASES

Human TLR10 is an anti-inflammatory pattern-recognition receptor

(2014) Marije Oosting et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Toll-Like Receptor Signaling Pathways

(2014) Takumi Kawasaki et al.   Frontiers in Immunology

Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity

(2013) R. Perret et al.   CANCER RESEARCH

TLR-mediated activation of NK cells and their role in bacterial/viral immune responses in mammals

(2013) Minou Adib-Conquy et al.   IMMUNOLOGY AND CELL BIOLOGY

Cooperation of TLR12 and TLR11 in the IRF8-Dependent IL-12 Response to Toxoplasma gondii Profilin

(2013) M. Raetz et al.   JOURNAL OF IMMUNOLOGY

TLR agonists: our best frenemy in cancer immunotherapy

(2013) Sabina Kaczanowska et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies

(2012) Brenda J. Weigel et al.   AMERICAN JOURNAL OF HEMATOLOGY

Distinct signaling pathways regulate TLR2 co-stimulatory function in human T cells

(2012) Nicole M. Chapman et al.   CELLULAR SIGNALLING

Recognition of Profilin by Toll-like Receptor 12 Is Critical for Host Resistance to Toxoplasma gondii

(2012) A. Alicia Koblansky et al.   IMMUNITY

Cutting Edge: TLR13 Is a Receptor for Bacterial RNA

(2012) A. Hidmark et al.   JOURNAL OF IMMUNOLOGY

Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity

(2011) Taro Kawai et al.   IMMUNITY

In vivo anti- and pro-tumour activities of the TLR2 ligand FSL-1

(2011) Kazuto Kiura et al.   IMMUNOBIOLOGY

TLR2 Stimulation Drives Human Naive and Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced Suppressive Function

(2011) M. H. Nyirenda et al.   JOURNAL OF IMMUNOLOGY

TLR1/TLR2 Agonist Induces Tumor Regression by Reciprocal Modulation of Effector and Regulatory T Cells

(2011) Y. Zhang et al.   JOURNAL OF IMMUNOLOGY

The Structural Biology of Toll-like Receptors

(2011) Istvan Botos et al.   STRUCTURE

Amplifying TLR-MyD88 Signals within Tumor-Specific T Cells Enhances Antitumor Activity to Suboptimal Levels of Weakly Immunogenic Tumor Antigens

(2010) D. Geng et al.   CANCER RESEARCH

Toll-like Receptor 2 Signaling in CD4+ T Lymphocytes Promotes T Helper 17 Responses and Regulates the Pathogenesis of Autoimmune Disease

(2010) Joseph M. Reynolds et al.   IMMUNITY

Differential but Direct Abolishment of Human Regulatory T Cell Suppressive Capacity by Various TLR2 Ligands

(2010) H. H. Oberg et al.   JOURNAL OF IMMUNOLOGY

The contribution of direct TLR signaling to T cell responses

(2009) Adeeb H. Rahman et al.   IMMUNOLOGIC RESEARCH

Toll-like receptor agonists in cancer therapy

(2009) Sylvia Adams   Immunotherapy

TLR2 Engagement on CD8 T Cells Enables Generation of Functional Memory Cells in Response to a Suboptimal TCR Signal

(2009) B. C. Mercier et al.   JOURNAL OF IMMUNOLOGY

Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis

(2009) Sunhwa Kim et al.   NATURE

Modulation of adaptive immunity with Toll-like receptors

(2009) Santhakumar Manicassamy et al.   SEMINARS IN IMMUNOLOGY

A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection

(2008) M. Quigley et al.   BLOOD

Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity

(2008) Nicole Asprodites et al.   FASEB JOURNAL

TLR2 – promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity

(2008) Ulrich Zähringer et al.   IMMUNOBIOLOGY

Mycoplasma infection suppresses p53, activates NF-κB and cooperates with oncogenic Ras in rodent fibroblast transformation

(2008) D Y Logunov et al.   ONCOGENE

Increased expression of Toll-like receptor 5 during progression of cervical neoplasia

(2007) W.Y. KIM et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER